Skip to main content

Advertisement

Log in

PRL Secreting Adenomas in Male Patients

Pituitary Aims and scope Submit manuscript

Abstract

Prolactinomas are the most frequent pituitary tumors and their frequency varies with age and sex, occurring most frequently in females between 20–50 yr-old. In men, hyperprolactinaemia is often present for many years without symptoms, as generally the most important symptoms are the decrease in libido and/or sexual potency both underestimated by the majority of the patients. Prolactin (PRL) plays a role in the process of spermatogenesis, and normal serum PRL levels are required for normal testicular function. On the other hand, hyperprolactinaemia has multiple negative effects on the gonadal axis. As a consequences hyperprolactinemic males show alteration of sexual potency and seminal fluid quality. Cabergoline treatments is able to induce normalization of PRL levels and a reduction of tumor mass in the majority of patients and consequently restoring the normal semen quality and ameliorating the quality of life of men with pituitary PRL-secreting adenoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998;352:1455–1461.

    Article  CAS  PubMed  Google Scholar 

  2. Colao A, Di Sarno A, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003;148(3):325–331.

    Article  CAS  PubMed  Google Scholar 

  3. Vance ML, Thorner MO. Prolactin: hyperprolactinemic syndromes and management. In: DeGroot LJ (ed.), Textbook of Endocrinology, 2nd edition. Philadelphia, London, Toronto, Mexico City, Rio de Janerio, Sydney, Tokyo, Hong Kong:WB Saunders Company, 1989, pp. 408–418.

    Google Scholar 

  4. Calle-Rodrigue RD, Giannini C, Scheithauer BW, et al. Prolactinomas in male and female patients: A comparative clinicopathologic study. Mayo Clin Proc. 1998;73:1046–52.

    Article  CAS  PubMed  Google Scholar 

  5. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study. J Clin Endocrinol Metab 1997;82:2102–2107.

    Article  CAS  PubMed  Google Scholar 

  6. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;84(7):2518–2522.

    Article  CAS  PubMed  Google Scholar 

  7. Molitch ME: Prolactinoma. In: Melmed S (ed.), The Pituitary, Boston: Blackwell Scientific, 1995, pp. 443–477.

    Google Scholar 

  8. Leonard MP, Nickel CJ, Marales A. Hyperprolactinemia and impotence: Why, when and how to investigate. J Urol 1989;142(4):992–994.

    CAS  PubMed  Google Scholar 

  9. Colao A, Vitale G, Cappabianca P, et al. Outcome of Cabergoline treatment in men with prolactinoma: Effects of a 24-months treatment on prolactin levels, tumor mass, recovery of pituitari function, and semen analysis. J Clin Endocrinol Metab 2004;89:1704–1711.

    CAS  PubMed  Google Scholar 

  10. Biller BMK, Molitch M, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81(6):2338–2343.

    Article  CAS  PubMed  Google Scholar 

  11. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19(3):225–268.

    Article  CAS  PubMed  Google Scholar 

  12. Hondo E, Kurohmaru M, Sakai S, Ogawa K, Hayashi Y. Prolactin receptor expression in rat spermatogenic cells. Biol Reprod 1995;52(6):1284–1290.

    Article  CAS  PubMed  Google Scholar 

  13. Winters SJ. Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men. J Androl 1991;12(3):185–190.

    CAS  PubMed  Google Scholar 

  14. Manandhar MS, Thomas JA. Effect of prolactin on the metabolism of androgens by the rat ventral prostate gland in vitro. Invest Urol 1976;14(1):20–22.

    CAS  PubMed  Google Scholar 

  15. Bartke A. Male hamster endocrinology. In: Siegel, H (ed.), The hamster, Reproduction and behaviour New York: Plenum Press, 1985, pp. 73–98.

    Google Scholar 

  16. Colao A, De Rosa M, Sarnacchiaro F, et al. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol 1996;135:548–552.

    Article  CAS  PubMed  Google Scholar 

  17. De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol. 1998;138:286–293.

    Article  CAS  PubMed  Google Scholar 

  18. De Rosa M, Zarrilli S, Vitale G, et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004;89:621–625.

    Article  CAS  PubMed  Google Scholar 

  19. Costello LC, Franklin RB. Effect of prolactin on the prostate. Prostate. 1994;24(3):162–166.

    CAS  PubMed  Google Scholar 

  20. Colao A, Vitale G, Di Sarno A, et al. Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab 2004;89(6):2770–2775.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Annamaria Colao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ciccarelli, A., Guerra, E., De Rosa, M. et al. PRL Secreting Adenomas in Male Patients. Pituitary 8, 39–42 (2005). https://doi.org/10.1007/s11102-005-5084-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-005-5084-3

Key Words

Navigation